Epidemiologic trends of cancer diagnoses among HIV-infected children in Spain from 1997 to 2008

Pediatric Infectious Disease Journal

Volumn 30, Issue 9, 2011, Pages 764-768

  Álvaro Meca, Alejandro ^a   Micheloud, Dariela ^b   Jensen, Julia ^c   Díaz, Asunción ^d   García Alvarez, Mónica ^b   Resino, Salvador ^b  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL INFANTA CRISTINA   (Spain)

^d CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

AIDSdefining malignancies; antiretroviral therapy; cancer; epidemiology; HIV

Indexed keywords

EFAVIRENZ; INDINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; ARTICULAR CARTILAGE; BONE CANCER; CANCER DIAGNOSIS; CANCER RISK; CHILDHOOD CANCER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SPAIN;

EID: 80051945058     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31821ba148     Document Type: Article

References (32)

1. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr. 2008;48:590-598.
2. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med. 2007;8:547-554. (Pubitemid 47616834)
3. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-422.
4. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306-5315.
5. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med. 2010;170:1337-1345.
6. Lanoy E, Spano J-P, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer. 2011: In press.
7. Long JL, Engels EA, Moore RD, et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008;22:489-496. (Pubitemid 351317290)
8. Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS. 2009;23:41-50.
9. Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDSdefining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr. 2009;52:203-208.
10. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528. (Pubitemid 33144917)
11. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284:190-197. (Pubitemid 30460862)
12. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.
13. Resino S, Resino R, Maria Bellon J, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis. 2006;43:243-252.
14. Chiappini E, Galli L, Tovo PA, et al. Cancer rates after year 2000 significantly decrease in children with perinatal HIV infection: a study by the Italian Register for HIV Infection in Children. J Clin Oncol. 2007;25: 97-101. (Pubitemid 350003056)
15. Subdirección General de Desarrollo. Instituto Nacional de Salud. Ministerio de Sanidad y Consumo. Conjunto Mínimo Básico de Datos Hospitales de Insalud 2001. Available at: http://www.ingesa.msc.es/ estadEstudios/docum Publica/CMBD-2001.htm.
16. Gil Prieto R, Alejandre CG, Meca AA, et al. Epidemiology of hospitaltreated Salmonella infection; data from a national cohort over a ten-year period. J Infect. 2009;58:175-181.
17. Gil-Prieto R, Garcia-Garcia L, Alvaro-Meca A, et al. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine. 2011;29:412-416.
18. Pritchard-Jones K, Kaatsch P, Steliarova-Foucher E, et al. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer. 2006;42:2183-2190. (Pubitemid 44224065)
19. Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 2003;4:110-119. (Pubitemid 36193171)
20. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008; 123:187-194. (Pubitemid 351705208)
21. Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDSrelated lymphoma. J Infect Dis. 2009;200:79-87.
22. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99:962-972. (Pubitemid 47073502)
23. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS. 2008;22:301-306.
24. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14:1065-1074.
25. van Leeuwen MT, Vajdic CM, Middleton MG, et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23:2183-2190.
26. Kest H, Brogly S, McSherry G, et al. Malignancy in perinatally human immunodeficiency virus-infected children in the United States. Pediatr Infect Dis J. 2005;24:237-242. (Pubitemid 40365858)
27. Resino S, Sanchez-Ramon S, Bellon JM, et al. Immunological recovery after 3 years' antiretroviral therapy in HIV-1-infected children. AIDS. 2002;16:483-486. (Pubitemid 34165382)
28. Resino S, Resino R, Micheloud D, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42:862-869. (Pubitemid 43363946)
29. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19:446-451. (Pubitemid 47356600)
30. Bedimo R. Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Curr HIV/AIDS Rep. 2008; 5:140-149.
31. Linet MS, Wacholder S, Zahm SH. Interpreting epidemiologic research: lessons from studies of childhood cancer. Pediatrics. 2003;112:218-232. (Pubitemid 36792916)
32. Li J, Thompson TD, Miller JW, et al. Cancer incidence among children and adolescents in the United States, 2001-2003. Pediatrics. 2008;121:e1470-e1477.